BCL2 and acute myeloid leukemia: The correlation of BCL-2 expression in AML patients with poorer overall survival (Antar et al. 2013;, Bankova et al. 2021)and the pre-clinical and clinical discoveries of synergy between BCL-2 inhibition and HMAs (Bohl et al. 2013;, Brenner et al. 2017)have resulted in the approval of AZA and venetoclax (a small molecule inhibitor or BCL-2) for the treatment of AML in 2017.